Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600–Mutant Unresectable or Metastatic Melanoma

Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf

Open source

DOI: 10.1200/jco.21.01601
Published: 2022-05-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.21.01601,
  title = {Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
                    <i>BRAF</i>
                    V600–Mutant Unresectable or Metastatic Melanoma},
  author = {Reinhard Dummer and Georgina V. Long and Caroline Robert and Hussein A. Tawbi and Keith T. Flaherty and Paolo A. Ascierto and Paul D. Nathan and Piotr Rutkowski and Oleg Leonov and Caroline Dutriaux and Mario Mandalà and Paul Lorigan and Pier Francesco Ferrucci and Jean Jacques Grob and Nicolas Meyer and Helen Gogas and Daniil Stroyakovskiy and Ana Arance and Jan C. Brase and Steven Green and Tomas Haas and Aisha Masood and Eduard Gasal and Antoni Ribas and Dirk Schadendorf},
  year = {2022},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.21.01601},
  url = {https://doi.org/10.1200/jco.21.01601}
}

RIS

TY  - JOUR
TI  - Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
                    <i>BRAF</i>
                    V600–Mutant Unresectable or Metastatic Melanoma
AU  - Reinhard Dummer
AU  - Georgina V. Long
AU  - Caroline Robert
AU  - Hussein A. Tawbi
AU  - Keith T. Flaherty
AU  - Paolo A. Ascierto
AU  - Paul D. Nathan
AU  - Piotr Rutkowski
AU  - Oleg Leonov
AU  - Caroline Dutriaux
AU  - Mario Mandalà
AU  - Paul Lorigan
AU  - Pier Francesco Ferrucci
AU  - Jean Jacques Grob
AU  - Nicolas Meyer
AU  - Helen Gogas
AU  - Daniil Stroyakovskiy
AU  - Ana Arance
AU  - Jan C. Brase
AU  - Steven Green
AU  - Tomas Haas
AU  - Aisha Masood
AU  - Eduard Gasal
AU  - Antoni Ribas
AU  - Dirk Schadendorf
PY  - 2022
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.21.01601
UR  - https://doi.org/10.1200/jco.21.01601
ER  -

APA

Dummer, R., Long, G. V., Robert, C., Tawbi, H. A., Flaherty, K. T., Ascierto, P. A., Nathan, P. D., Rutkowski, P., Leonov, O., Dutriaux, C., Mandalà, M., Lorigan, P., Ferrucci, P. F., Grob, J. J., Meyer, N., Gogas, H., Stroyakovskiy, D., Arance, A., Brase, J. C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., & Schadendorf, D. (2022). Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600–Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01601

Source records

crossref · retrieved 2026-09-26T03:42:10.101Z